- Trials with a EudraCT protocol (51)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
51 result(s) found for: Reference material.
Displaying page 2 of 3.
EudraCT Number: 2009-011580-36 | Sponsor Protocol Number: 40071 | Start Date*: 2011-04-26 | |||||||||||
Sponsor Name:EORTC - European Organisation for Research and Treatment of Cancer | |||||||||||||
Full Title: Effectiveness of first line treatment with lapatinib and ECF/X in histologically proven adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surge... | |||||||||||||
Medical condition: adenocarcinoma of the stomach or the esophagogastric junction (metastatic or not amenable to curative surgery) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Prematurely Ended) DE (Completed) HU (Prematurely Ended) PT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000012-24 | Sponsor Protocol Number: DOXATTR | Start Date*: 2006-01-24 | |||||||||||
Sponsor Name:OSPEDALE POLICLINICO S. MATTEO | |||||||||||||
Full Title: A phase II study of the safety and efficacy of doxycycline administered cyclically in patients suffering from Transthyretin Amiloidosis ATTR | |||||||||||||
Medical condition: Transthyretin amyloidosis ATTR | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002544-32 | Sponsor Protocol Number: UCL/15/0515 | Start Date*: 2018-03-01 | ||||||||||||||||
Sponsor Name:University College London | ||||||||||||||||||
Full Title: A phase II study of nivolumab monotherapy in patients with relapsed/refractory Hodgkin lymphoma, fit for autologous stem cell transplant, who fail to reach complete metabolic remission after first ... | ||||||||||||||||||
Medical condition: Relapsed/refractory Hodgkin lymphoma | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-000678-19 | Sponsor Protocol Number: MCL2008-01 | Start Date*: 2010-08-05 | ||||||||||||||||
Sponsor Name:Klinikum der Universität München, Klinikum Großhadern | ||||||||||||||||||
Full Title: Feasibility and efficacy of Lenalidomide maintenance after salvage immuno-chemotherapy induction in relapsed or refractory mantle cell lymphoma - a phase II study of the European MCL Network | ||||||||||||||||||
Medical condition: patients with relapsed or refractory mantle cell lymphoma after or not eligible for myeloablative treatment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DE (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-004660-19 | Sponsor Protocol Number: NCT-2016-415 | Start Date*: 2017-11-22 | |||||||||||
Sponsor Name:University Hospital Heidelberg | |||||||||||||
Full Title: CDK4/6 inhibition in locally advanced/metastatic chordoma | |||||||||||||
Medical condition: Patients with locally advanced or metastatic chordoma refractory to treatment with tyrosine kinase inhibitors. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004368-21 | Sponsor Protocol Number: ISG-ACCesS | Start Date*: 2020-09-15 | |||||||||||
Sponsor Name:ITALIAN SARCOMA GROUP | |||||||||||||
Full Title: Phase II study on TSR-042 in advanced clear cells sarcoma | |||||||||||||
Medical condition: Advanced clear cells sarcoma | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001547-43 | Sponsor Protocol Number: ET19-075 | Start Date*: 2022-01-18 | |||||||||||
Sponsor Name:Centre Léon Bérard | |||||||||||||
Full Title: ATEZOGIST – A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib resumption alone in patients with unresectabl... | |||||||||||||
Medical condition: Unresectable locally advanced or metastatic gastrointestinal stromal tumors (GIST) after failure of standard treatments | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-018314-75 | Sponsor Protocol Number: MT103-203 | Start Date*: 2010-08-05 | |||||||||||
Sponsor Name:Amgen Research (Munich) GmbH | |||||||||||||
Full Title: A confirmatory multicenter, single-arm study to assess the efficacy, safety, and tolerability of the BiTE® antibody blinatumomab in adult patients with minimal residual disease (MRD) of B-precursor... | |||||||||||||
Medical condition: minimal residual disease (MRD) of B-precursor ALL | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) CZ (Completed) FR (Completed) PL (Completed) IT (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004868-30 | Sponsor Protocol Number: PNET5MB | Start Date*: 2013-10-31 | |||||||||||
Sponsor Name:University Medical Center Hamburg-Eppendorf | |||||||||||||
Full Title: AN INTERNATIONAL PROSPECTIVE TRIAL ON MEDULLOBLASTOMA (MB) IN CHILDREN OLDER THAN 3 TO 5 YEARS WITH WNT BIOLOGICAL PROFILE (PNET 5 MB – LR and PNET 5 MB – WNT-HR), AVERAGE-RISK BIOLOGICAL PROFILE (... | |||||||||||||
Medical condition: Children with medulloblastoma. Medulloblastoma is a highly cellular malignant embryonal neoplasm. | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) BE (Trial now transitioned) IT (Trial now transitioned) FR (Trial now transitioned) FI (Trial now transitioned) SE (Trial now transitioned) ES (Ongoing) GB (GB - no longer in EU/EEA) AT (Ongoing) NO (Completed) CZ (Trial now transitioned) NL (Trial now transitioned) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-004154-41 | Sponsor Protocol Number: ISO-CC-007 | Start Date*: 2018-11-07 | |||||||||||
Sponsor Name:Isofol Medical AB | |||||||||||||
Full Title: A randomized, multicenter, parallel-group, Phase III study to compare the efficacy of arfolitixorin versus leucovorin in combination with 5 fluorouracil, oxaliplatin, and bevacizumab in patients wi... | |||||||||||||
Medical condition: First line advanced Colorectal patients eligible for treatment with 5-FU, oxaliplatin, and bevacizumab. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Prematurely Ended) DE (Prematurely Ended) FR (Prematurely Ended) AT (Prematurely Ended) GR (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-002609-31 | Sponsor Protocol Number: ISO-44-013 | Start Date*: 2012-01-27 | |||||||||||
Sponsor Name:Guerbet | |||||||||||||
Full Title: Diagnostic contribution of XENETIX® CT PERFUSION in pre-therapeutical assessment of hepatocellular carcinoma. | |||||||||||||
Medical condition: Subjects diagnosed for HCC and planned for surgery (tumorectomy, sectionectomy, segmentectomy, lobectomy or transplantation). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-003210-13 | Sponsor Protocol Number: LYT-100-2020-02 | Start Date*: 2020-10-27 | |||||||||||
Sponsor Name:PureTech LYT 100, Inc. | |||||||||||||
Full Title: A Phase 2 Randomized, Double-blind, Placebo-controlled Trial and Open Label Extension to Evaluate the Safety and Efficacy of Deupirfenidone (LYT- 100) in Post-acute COVID-19 Respiratory Disease | |||||||||||||
Medical condition: COVID-19 respiratory disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: RO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005036-28 | Sponsor Protocol Number: 2012/41 | Start Date*: 2013-04-12 | |||||||||||
Sponsor Name:CENTRE ANTOINE LACASSAGNE | |||||||||||||
Full Title: Pharmacogenetic study in castration-resistant prostate cancer patients treated with abiraterone acetate | |||||||||||||
Medical condition: Prostate cancer metastatic | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-005216-15 | Sponsor Protocol Number: ABO-NB-15 | Start Date*: 2016-07-06 | |||||||||||||||||||||
Sponsor Name:ABOCA S.P.A. SOCIETà AGRICOLA | |||||||||||||||||||||||
Full Title: Relief of heartburn and epigastric pain comparing Neobianacid® with omeprazole: a randomized, double blind, double dummy, reference product controlled, parallel group, non-inferiority clinical study | |||||||||||||||||||||||
Medical condition: GERD (Gastroesophageal Reflux Disease) and/or EPS (Epigastric Pain Syndrome) | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: IT (Completed) | |||||||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002257-37 | Sponsor Protocol Number: UC-0105/1611 | Start Date*: 2017-02-10 |
Sponsor Name:UNICANCER | ||
Full Title: Secured access to nivolumab for adult patients with selected rare cancer types | ||
Medical condition: Unresectable locally advanced or metastatic, non-clear cell renal cell carcinoma, rare head and neck cancer, rare skin cancer, MSI-nonCRC or penile cancer, which is resistant or refractory to stand... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-004849-11 | Sponsor Protocol Number: AIO-KRK-0116 | Start Date*: 2016-09-29 | |||||||||||
Sponsor Name:University Clinic od Munich-Großhadern (represented by the medical management) | |||||||||||||
Full Title: Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE-4.5) | |||||||||||||
Medical condition: Histologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum with metastases (metastatic colorectal cancer, mCRC), primarily non-resectable or surgery refused by the patient; RAS ... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001749-26 | Sponsor Protocol Number: MK-3475-040 | Start Date*: 2014-11-21 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase III Randomized Trial of MK-3475 (Pembrolizumab) versus Standard Treatment in Subjects with Recurrent or Metastatic Head and Neck Cancer | |||||||||||||
Medical condition: Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Completed) LT (Completed) DE (Completed) BE (Completed) PT (Completed) NL (Completed) HU (Completed) IT (Completed) ES (Completed) FR (Completed) PL (Completed) SE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-000068-86 | Sponsor Protocol Number: AROAAT2002 | Start Date*: 2019-07-01 | |||||||||||
Sponsor Name:Arrowhead Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Pilot Open Label, Multi-dose, Phase 2 Study to Assess the Safety and Efficacy of ARO-AAT in Patients with Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD) | |||||||||||||
Medical condition: alpha-1 antitrypsin deficiency (AATD)-associated liver disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-005476-33 | Sponsor Protocol Number: I4C-MC-JTBB | Start Date*: 2013-08-27 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non–Small Cell Lung Cancer Patients with Activating EGFR Mutations ... | |||||||||||||
Medical condition: Non-Small Cell Lung Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Ongoing) IT (Completed) FR (Completed) ES (Ongoing) DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001929-32 | Sponsor Protocol Number: 2014/2126 | Start Date*: 2014-08-25 | |||||||||||
Sponsor Name:Gustave Roussy | |||||||||||||
Full Title: Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication | |||||||||||||
Medical condition: Diffuse Intrinsic Pontine Glioma | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) DK (Trial now transitioned) SE (Trial now transitioned) GB (GB - no longer in EU/EEA) NL (Prematurely Ended) ES (Temporarily Halted) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
